Literature DB >> 23229179

Haematology: Ponatinib--the next TKI challenge.

Mina Razzak.   

Abstract

Entities:  

Year:  2012        PMID： 23229179     DOI： 10.1038/nrclinonc.2012.226

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245
  1 in total
  3 in total

1.  Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Authors:  Geoffrey D Miller; David W Woessner; Monika J Sirch; Carol S Lim
Journal:  Mol Pharm       Date:  2013-08-20       Impact factor: 4.939

2.  Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Authors:  Octavian Bucur; Andreea Lucia Stancu; Ioana Goganau; Stefana Maria Petrescu; Bodvael Pennarun; Thierry Bertomeu; Rajan Dewar; Roya Khosravi-Far
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

3.  Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites.

Authors:  Rumen Kostov; Jeffrey T-J Huang; Colin J Henderson; C Roland Wolf
Journal:  J Pharmacol Exp Ther       Date:  2017-10       Impact factor: 4.030
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.